PMH55 CANADIAN COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE VERSUS ORAL ATYPICAL AND CONVENTIONAL DEPOT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA AT HIGH-RISK OF NON-COMPLIANCE- UPDATED BASED ON NEW CLINICAL DATA

May 1, 2010, 00:00 AM
10.1016/S1098-3015(10)72550-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)72550-X/fulltext
Section Title :
Section Order : 87
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72550-X&doi=10.1016/S1098-3015(10)72550-X
HEOR Topics :
Tags :
Regions :